Growing Medical Portfolio Avicanna has a broad and growing physician- and patient-facing medical cannabis and wellness portfolio (RHO Phyto) with nationwide Canada reach and expansion into international markets, presenting multiple entry points for B2B collaborations, co-marketing, and institutional distribution agreements.

Pharma Pipeline Focus With an indication-specific, patent-pending pharmaceutical candidate pipeline in dermatology, chronic pain, and neurological disorders, there are opportunities to unlock partnerships in clinical development, licensing, contract manufacturing, and regional commercialization in suitable markets.

Integrated Care Platform MyMedi.ca and integrated healthcare program capabilities enable hospital and clinic collaborations, pharmacist-led support, and reimbursement pathways, offering a ready channel for veterinary and human medical system partnerships, payer conversations, and care-network integration.

Financial Growth Signals Recent quarterly revenue of approximately six to seven million with a positive gross profit and continued investments in product launches and infrastructure, signaling capacity for scaled sales, channel expansion, and cross-sell of new QUIX powered and dermatology-focused products.

Leadership and Execution New CFO appointment and ongoing toolchain modernization (Salesforce, NetSuite, e-commerce, and digital marketing), indicating a professionalized go-to-market engine and improved ability to track, forecast, and monetize business development opportunities globally.